Skip to main content

Home
About Us
Research
- Complement System
  - AMD
  - Systemic Diseases
- Complement Precision Medicine (CPM) Platform
News
Contact Us
- For Patients

Home
About Us
Research
- Complement System
  - AMD
  - Systemic Diseases
- Complement Precision Medicine (CPM) Platform
News
Contact Us
- For Patients

Careers

We currently have no job openings

Complement Therapeutics Receives UK CTA Approval to Advance CTx001 into Opti-GAIN Phase I/II Clinical Trial in Geographic Atrophy Secondary to AMD
Complement Therapeutics Announces FDA Fast Track Designation for CTx001 for the Treatment of Geographic Atrophy Secondary to AMD
Complement Therapeutics Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy secondary to AMD
Complement Therapeutics Appoints Dr Muhammad Ali Memon FRCOphth, as Chief Medical Officer
Touchlight, Cell and Gene Therapy Catapult and Complement Therapeutics to develop innovative manufacturing process for gene therapies

Complement Therapeutics GmbH

Sternstrasse 21

80538 Munich

Germany

Complement Therapeutics Ltd
Central Working White City
Translation and Innovation Hub
84 Wood Lane
London, W12 0BZ
United Kingdom

Complement Therapeutics Ltd
LabG16
Stevenage Bioscience Catalyst
Gunnels Wood Rd,
Stevenage SG1 2FX
United Kingdom

info@complementtx.com
Complement Therapeutics
@ComplementTx
Privacy Policy

Created by HTP Digital